SCHERING-Plough recently announced that the pegylated interferon alfa-2b drug has been approved by the Malaysian Drug Control Authority for the treatment of chronic hepatitis B (CHB) in Malaysia.
Chronic hepatitis B is a serious infectious disease and the leading cause of liver cancer in Malaysia.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!